GGiantBullStocks

Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ · Healthcare

$293.99-3.10%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$6.31B
P/E ratio
EPS
Volume
395,571
52-week high
52-week low
Open
$303.51
Day high
$305.65
Day low
$293.70

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025$268.09M$124.45M$6.13
2024$167.13M-$4.03M-$0.22
2023$131.31M$52.15M$2.94
2022$196.25M-$33.36M-$1.98
2021$241.54M$57.14M$3.31

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

CEO
Todd C. Davis
Employees
47
Country
US
IPO date
Nov 18, 1992

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Ligand Pharmaceuticals Incorporated's stock price today?
LGND is trading at $293.99 as of Jul 20, 2026.
What is Ligand Pharmaceuticals Incorporated's market cap?
Ligand Pharmaceuticals Incorporated (LGND) has a market capitalization of $6.31B.
Does Ligand Pharmaceuticals Incorporated pay a dividend?
Ligand Pharmaceuticals Incorporated did not pay a dividend in its most recent reported fiscal year.
What sector is Ligand Pharmaceuticals Incorporated in?
Ligand Pharmaceuticals Incorporated operates in the Healthcare sector.